Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

Recruiting now

Conditions studied: Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC)

In brief

Study on the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-NY104 PET/CT in diagnosing primary, recurrent, and metastatic lesions of renal cell carcinoma; and investigate the effect of oral low-dose CAIX inhibitor (Acetazolamide) on the tissue distribution of 18F-NY104 in renal cell carcinoma patients, particularly in the stomach and kidneys.

Key facts

Study ID: NCT06916624
Run by: The Affiliated Hospital of Qingdao University
People needed: 40
Starts: 2025-04-12
Expected to finish: 2026-12-01
Last updated by the study team: 2025-04-29

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

(1)Capable of understanding and voluntarily signing the informed consent form; able to complete the trial in accordance with the protocol requirements; (2)Age 18-75 years; no gender restrictions; (3)Clinically diagnosed/suspected as renal cell carcinoma or clinically diagnosed/suspected recurrence/metastasis after RCC treatment; (4)At least 1 measurable solid lesion in the subject, which can be accurately and continuously measured using modified RECIST criteria (version 1.1); (5)ECOG performance status score of 0-2; (6)Laboratory parameters must meet:
Hematology: WBC ≥4.0×10⁹/L or neutrophils ≥1.5×10⁹/L, PLT ≥100×10⁹/L, Hb ≥90g/L; PT or APTT ≤1.5×ULN (upper limit of normal);
Liver and kidney function: T-Bil ≤1.5×ULN, ALT/AST ≤2.5×ULN or ≤5×ULN (for subjects with liver metastasis), ALP ≤2.5×ULN (if bone or liver metastasis present, ALP ≤4.5×ULN); BUN ≤1.5×ULN, SCr ≤1.5×ULN;
Other routine tests within normal ranges or deemed acceptable by the investigator; (7)Expected survival ≥12 weeks; (8) Female subjects: Effective contraception (defined as sterilization, intrauterine hormone device, condoms, contraceptives/agents, abstinence, or partner vasectomy) must be used during the study and for 6 months post-study; Male subjects: Agreement to use contraception during the study and for 6 months post-study.

You may not qualify if…

Recovery from major trauma (including surgery) within 4 weeks prior to study examination;
Patients with systemic or local severe infections or other serious comorbidities;
Severe hepatic or renal dysfunction;
Refusal to participate in this clinical study;
Patients with a history of allergy to any component of the imaging agent (including antibodies) or allergic constitution;
Childbearing-aged male or female subjects who cannot adopt effective contraception;
Women planning pregnancy, currently pregnant, or lactating;
Patients unable or unwilling to undergo PET/CT scanning;
Other subjects deemed ineligible by the investigator.

Where it is running

The Affiliated Hospital of Qingdao University — Qingdao, Shandong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.